FunPep Company Limited
【FanPep】Clinical Trial Milestone for Antibody-Inducing Peptide | July 2026
Announced preliminary results of Phase I clinical trial of the antibody-inducing peptide FPP004X. Good safety profile, confirmed increase in anti-IgE antibody levels. Future development plans to be discussed.
Key Figures
- Positive rate of anti-IgE antibodies: Part 1 97% (35/36 cases), Part 2 100% (24/24 cases)
- Incidence of adverse reactions: No clinical issues aside from local and systemic reactions
- Discontinuation due to adverse events: None
AI要約
Overview of the Clinical Trial
FanPep Co., Ltd. announced preliminary results of a Phase I clinical trial of the antibody-inducing peptide FPP004X for hay fever. The study evaluated safety and immunogenicity across multiple dosing cohorts in healthy adults and hay fever patients. Safety was excellent with no discontinuations due to side effects or adverse events. An increase in anti-IgE antibody levels was also observed, indicating immune response. No symptom improvement was noted after exposure to cedar pollen. Moving forward, discussions with Shionogi & Co., Ltd. will determine the future development strategy.
Future Outlook and Corporate Activities
The results of this trial will not impact the financial results for the fiscal year ending December 2026. FanPep is partnering with Shionogi & Co., Ltd. to develop and commercialize FPP004X globally. Details regarding further clinical development and partnership agreements will continue to be disclosed.
FanPep Co., Ltd.
Company overview · Stock price · Financial data · All IR
